Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials)

[1]  F. Lo‐Coco,et al.  Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. , 2005, Blood.

[2]  A. Vekhoff,et al.  Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience , 2003, Leukemia.

[3]  C. Bloomfield,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol , 2022 .

[4]  M. Baccarani,et al.  Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. , 2002, Blood.

[5]  H. Dombret,et al.  Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia , 2000, Leukemia.

[6]  J. Miguel,et al.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.

[7]  P. Fenaux,et al.  Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group , 1993 .

[8]  R. Berger,et al.  [Acute promyelocytic leukemia: retrospective study of 119 patients treated with daunorubicin]. , 1984, Nouvelle revue francaise d'hematologie.